期刊文献+

纳米药物研发与商业化趋势统计分析 被引量:1

Analysis on the Development and Commercialization Trends of Nanodrugs
下载PDF
导出
摘要 纳米药物是纳米技术在医药领域的应用。与常规药物相比,纳米药物在实现靶向给药、缓控释给药、提高药物溶解度及生物利用度、降低毒副作用等方面具有良好的发展前景。本研究通过统计数据分析纳米药物从理论研究探索到商业上市各阶段的发展状况,包括纳米药物数量、重要研发国家与公司、主要适应症与作用机制的分布、具有较高商业价值的热点药物等,分析纳米药物的总体发展趋势,揭示其竞争态势和主要发展方向。 Nanodrug research is an application of nanotechnology in medical area.Compared with conventional drugs,nanodrug have promising development prospects in many aspects,including but not limited in targeted drug delivery,controlled release of drugs,improvement of drug solubility and bioavailability,and reduction of toxic effects.Through the statistical data of the nanodrug development in different stages,from theory exploration to the commercialization,this study analyze the status of nanodrug quantity,important R&D countries and companies,distribution of the main indications and mechanism,and hot drugs with high commercial value,and further discuss the overall development trends of nanodrug,reveal the global competition situation and main development directions.
作者 邢颖 吴树仙 李超 冷伏海 赵宇亮 Xing Ying;Wu Shuxian;Li Chao;Leng Fuhai;Zhao Yuliang(Institutes of Science and Development, CAS, Beijing 100190, China;National Center for Nanoscience and Technology, Beijing 100190, China)
出处 《工程研究(跨学科视野中的工程)》 CSCD 2017年第6期586-600,共15页 JOURNAL OF ENGINEERING STUDIES
关键词 纳米药物 纳米技术 靶向治疗 药学 nanodrug nano-technology targeted therapy pharmacy
  • 相关文献

参考文献4

二级参考文献89

  • 1陈永法,龚明涛,张钧寿,高忠明,王猛.紫杉醇冻干纳米乳的制备及理化性质[J].中国天然药物,2005,3(4):235-237. 被引量:14
  • 2李战军.纳米药物的制备方法[J].武汉工业学院学报,2006,25(2):30-34. 被引量:3
  • 3刘斌.紫杉醇新剂型——紫杉醇脂质体(力扑素)临床应用观察[J].中国医院用药评价与分析,2007,7(1):59-60. 被引量:25
  • 4WANI MC, TAYLOR HL, WALL ME, et al. Plant antitumor agents. Ⅵ. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia[J]. J Am Chem Soc, 1971, 93(9) : 2325-2327.
  • 5ten TIJE A J, VERWEIJ J, LOOS W J, et al. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy[J]. Clin Pharmaeokinet, 2003, 42(7): 665-685.
  • 6IBRAHIM NK, DESAI N, LEGHA S, et al. Phase Ⅰ and phannacokinetic study of ABI-007, a Cremophnr-free, proteinstabilized, nanopartiele formulation of paclitaxel[J]. Clin Cancer Res, 2002, 8(5): 1038-1044.
  • 7GRADISHAR WJ. Albumin-bound paclitaxel: a next-generation taxane[J]. Expert Opin Pharmacother, 2006, 7(8): 1041-1053.
  • 8SOC1NSKI M. Update on nanoparticle albumin-bound paclitaxel [J]. Clin Adv Hematol Oncol, 2006, 4(10): 745-746.
  • 9VILLANO JI,, MEHTA D, RADHAKRISHNAN L. Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency[J]. Invest New Drugs, 2006, 24 (5): 455-456.
  • 10TRICKLER WJ, NAGVEKAR AA, DASH AK. A novel nanoparticle formulation tor sustained paclitaxel delivery [J].AAPS PharmSciTeeh, 2008, 9(2): 486-493.

共引文献22

同被引文献19

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部